 |
|
Peripheral Neuropathy as an Early Marker of AL Amyloidosis
Margaret A. Duston, MD;
Martha Skinner, MD;
Jennifer Anderson, PhD;
Alan S. Cohen, MD
Arch Intern Med. 1989;149(2):358-360.
Abstract
• Fifty-one of 146 patients with primary amyloid deposits of light-chain origin (AL) examined between 1972 and 1986 were found to have peripheral neuropathy as part of their systemic amyloidosis. Peripheral neuropathy was the presenting symptom in 11 patients, and it was a later symptom or an incidental physical examination finding at the time of amyloid workup in 40 additional patients. The median duration of time from first symptom to the diagnosis of primary amyloidosis was longer in those whose first symptom was neuropathy (48 months vs 12 months). In addition, survival time after diagnosis for these patients was significantly longer (at least 35 months vs 16 months). Peripheral neuropathy is not an uncommon symptom of primary amyloidosis and may mark the onset of the disease process years before infiltration of vital structures of the heart, kidneys, or gastrointestinal tract leads to failure and a subsequent downhill course. Appreciating amyloid disease at this early stage may widen the potential therapeutic window.
(Arch Intern Med 1989;149:358-360)
Author Affiliations
From the Arthritis Center of Boston University School of Medicine.
Footnotes
Accepted for publication Aug 5, 1988.
Presented in part at the American Rheumatism Association meeting, Washington, DC, June 12, 1987.
Reprint requests to Arthritis Center K503, Boston University School of Medicine, 71 E Concord St, Boston, MA 02118 (Dr Skinner).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis
Ward et al.
Blood 2011;118:6610-6617.
ABSTRACT
| FULL TEXT
Chapter 21 Polyneuropathy
Donaghy
Brain's Diseases of the Nervous System 2009;12:med-9780198569381-chapter-med-9780198569381-chapter.
ABSTRACT
| FULL TEXT
Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis
Gertz et al.
JCO 1999;17:262-262.
ABSTRACT
| FULL TEXT
Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients
Comenzo et al.
Blood 1998;91:3662-3670.
ABSTRACT
| FULL TEXT
|
